Myriad Genetics (MYGN) Reports Q2 Loss, Tops Revenue Estimates

By Nasdaq8 days ago

AD

Myriad Genetics (MYGN) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.

Continue read on nasdaq.com